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Summary The G1465A polymorphism in the gene of the GABA type B receptor
subunit 1 (GABABR1) has been linked to the risk for temporal lobe epilepsy (TLE).
However, six replication studies did not show significant association between the
G1465A GABABR1 gene variant and TLE. The authors examined this association in a
sample of 102 patients with mesial TLE with hippocampal sclerosis (MTLE-HS) and 71
controls. The genotype distribution varied significantly between patients and con-
trols. Heterozygous carriers of the A-allele had a 10-fold increase in risk for MTLE-HS
(OR 10.01; 95% CI 3.98—25.18, p = 3.788E08).
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
The syndrome of mesial temporal lobe epilepsy with
hippocampal sclerosis (MTLE-HS) is considered an
acquired disorder. Nevertheless, recent evidence
indicates that genetic factors are important in the
genesis of this syndrome.1
GABA is the main inhibitory aminoacid of the
central nervous system. Its action, mediated
through GABA type B receptors, could be important
in the epileptogenesis of MTLE-HS.2
An association between the G1465A polymorph-
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reported in 2003.3 Nevertheless, six recent reports
have failed to confirm this association, raising con-
troversy about the real role of this polymorphism in
the susceptibility to develop the disease.4—9
The aim of the present study, which started in
2003, was to examine the association between the
G1465A GABABR1 gene single nucleotide polymorph-
ism and the MTLE-HS susceptibility in a population of
Argentinean patients with MTLE-HS. We also
included an exploratory analysis in other phenotypic
subgroups.Materials and methods
Between August 2003 and July 2005, we recruited
102 consecutive MTLE-HS patients from the Epilepsy
Clinic at the Neurology Division of the Ramos Mejia
Hospital in Buenos Aires, Argentina. The study was. Published by Elsevier Ltd. All rights reserved.
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tee and written informed consent was obtained
from each patient prior to any sample recovery.
All patients had a comprehensive diagnostic evalua-
tion, including detailed seizure history and neuro-
logical examination, neuropsychological testing,
optimized MRI study, and surface EEG. Long-term
video-EEG monitoring was performed in a subset of
patients. Data from all these patients was consistent
with the diagnosis of typical MTLE-HS. Seventy-one
healthy unrelated subjects were selected as con-
trols. Selection of the controls was based on the lack
of any positive antecedent for a seizure event or
other neurologic or psychiatric disorder. Cases and
controls were interviewed about ethnic back-
ground. We paid special attention to the nationality
of parents and grandparents of the subjects
included. Control subjects were matched for age,
gender, ethnic origin (nationality of parents and
grandparents), and area of residence.
The following clinical features were analyzed:
age, sex, age at onset of epilepsy, prior history of
febrile seizures, positive family history for epilepsy
and febrile seizures, clinical semiology of seizures,
seizure frequency, and response to pharmacological
treatment.
Genomic DNA was isolated from whole blood
using a Flexigene kit, as described by the manufac-Table 1 Genotype frequencies in populations studied
Genotypes MTEHS, N = 102 (%) Controls, N =
A/A 0 0
A/G 49 (48) 6 (8.5)
G/G 53 (52) 65 (91.5)
NA: not applicable; MTEHS: mesial temporal lobe epilepsy with hip
a x2-test.
b Crude odds ratio.
Table 2 Baseline characteristics of patients with MTEHS
association studies cohorts reported in the literature
Study n Male, n (%) HS, n (%) Age at
year, m
Stogmann et al. 188 78 (41.5) 112 (59.6) 15.1 (
Jin et al. 112 64 (57.1) 67 (59.8) 16.46
Salzmann et al. 110 47 (42.7) 108 (98.2) 15.05
Cavallieri et al. 245 NR NR NR
Tan et al. 234 96 (41) 140 (59.8) 15 (13
Ma et al. 120 49 (40.8) NR 22,8 (
Gambardella et al. 141 63 (44.7) 31 (22) 30.9 (
Kauffman et al. 102 51 (50) 102 (100) 16.4 (
NR: no reported; FH: family history positive for epilepsy or febrile
a 176 patients investigated, in 12 patients clinical details regardi
b 184 patients investigated, in 4 patients reliable information couturer (Qiagen, Hilden, Germany). The G1465A
GABABR1 polymorphism was genotyped by PCR-
RFLP, as previously described.3 The PCR and RFLP
reactions were performed in a blinded manner to
clinical features, in batches containing equal num-
ber of samples from patients and controls.
The Hardy—Weinberg equilibrium in the cohort of
healthy controls was tested using exact test. Cate-
gorical variables were compared with the x2-test or
Fisher exact test. We calculated ORs as measures of
effect. An a level ( p-value) of<0.01 was considered
as significant, as standardized for genetic associa-
tion studies. All p-values were two-tailed. Differ-
ences in quantitative variables were assessed with
the Mann—Whitney U test, since data did not have a
normal distribution. All statistical analyses were
performed using the SPSS version 10.0 for Windows.Results
The distribution of genotypes and allele frequencies
of the G1465A polymorphism in exon 7 of the human
GABABR1 gene in patients and controls is summarized
in Table 1. Heterozygous carriers of the A allele had a
10-fold increased risk for MTLE-HSwhen compared to
homozygous carriers of the G allele (GG vs. GA: OR
10.01; 95% CI 3.98—25.18 p = 3.788E08). The71 (%) OR (95% CI) p-Value
NA 3.788E08a
10.016 (3.98—25.18)b
1 (reference group)b
pocampal sclerosis.
in the present study, compared with GABBR1 G1465A
onset,
ean (S.D.)
FH, n (%) FC, n (%) Medically
refractory, n (%)
13.5) 48 (25.5)a 42 (22.3)b 175 (93.1)
(8.99) NR 28 (25) NR
(5.23) 22 (20) 60 (54.5) 110 (100)
NR NR NR
.5) NR 82 (35) 159 (68)
10.08) 66 (55) 120 (100) 23 (19.2)
21.9) 51 (36.2) 21 (14.9) 14 (9.9)
13.37) 18 (17.6) 20 (19.6) 60 (58.8)
convulsions; FC: antecedent of febrile convulsions.
ng family history could not be assessed unambiguously.
ld not be obtained.
GABABR1 gene variation and TLE 569observed genotype distributions in the cohort of
controls and the respective theoretical distributions
inferred from the observed allele frequencies were
not significantly different (Hardy—Weinberg equili-
brium). We did not examine other genetic variants.
Baseline characteristics of our patients compared
with the clinical characteristics of the different
cohorts where this GABABR1 gene variant was inves-
tigated are summarized in Table 2.
In the exploratory analysis, we found that A/G
genotype was not associated with either a family
history of epilepsy or febrile seizures. Furthermore,
we did not find an association between this geno-
type and severity of epilepsy, as measured by sei-
zure frequency, clinical semiology of seizures, and
response to pharmacological treatment (our cohort
is formed by a 60% of medically refractory subjects)
or ethnic origin of subjects included.Discussion
The association between temporal lobe epilepsy and
the GABABR1 G1465A polymorphism was originally
reported by Gambardella et al. in a cohort of Italian
patients that included a small number of patients
with hippocampal sclerosis.3 Our results, obtained
from an independent population, confirm the origi-
nal findings. Although our estimate of the size effect
is of a smaller magnitude than the one reported in
the first study, the prevalence of G1465A poly-
morphism in our patients is greater suggesting a
more homogeneous population.
Nevertheless, six recent studies failed to find an
association between G1465A polymorphism and
temporal lobe epilepsy in groups of patients with
different ethnic origins. The G1465A polymorphism
was not associated with a risk to develop temporal
lobe epilepsy, irrespective of the presence or
absence of hippocampal sclerosis, in studies per-
formed in the United States, France, Great Britain,
Australia, China, and Austria. Ethnic differences
may play a role in conflicting results of genetic
association studies. These differences could be
due to linkage disequilibrium of the disease causing
allele with different alleles at the marker locus in
different populations. Alternatively, allelic hetero-
geneity among different ethnic groups, or other
genetic or environmental factors modifying the
association could explain differences among stu-
dies.10 Since our cohort is similar on clinical grounds
with the ones mentioned above (see Table 2), the
differences observed could depend on ethnic fac-
tors. In the XIX and XX century, Argentina received a
large number of immigrants, being Italy the main
source of this flow. Furthermore, a populationgenetic study performed in the city of Buenos Aires
showed that the genetic contribution of Europeans
to the gene pool of Buenos Aires could be estimated
at 67.55%.11 We think that our positive finding might
be due to this ethnic similarity with Gambardella’s
population as a consequence of our particular
migratory history.
Alternatively, we must consider the possibility of
false positive results in our study. Several authors
have suggested possible reasons for inconsistency in
the results of genetic association studies.10 One of
the most common causes for failure to reproduce
initial findings is population stratification.6 How-
ever, this can represent an important bias only under
extreme situations, such as populations with few
ethnic groups with large differences in disease and
genotype frequencies among them.12 Moreover,
simulation studies performed in highly admixed
populations, like ours, also conclude that bias as a
result of population stratification is highly unlikely,
even under unrealistic scenarios such as two ethni-
cities structured with marked differences in disease
rates between them.12 We think that population
stratification is not an important factor in our find-
ings because our population is composed by more
than two ethnic groups with no large ethnic differ-
ences of temporal lobe epilepsy prevalence
reported.
Another explanation for false positive findings is
chance.10 In order to control for this factor some
researchers suggested accepting only highly conser-
vative p-values to reject the null hypothesis of no
association. The most stringent threshold value
should be 5  108.13 We think that the level of
significance in our study (4  108) makes unlikely
that our positive findings could be due to chance.
The possibility of biased genotyping errors is very
unlikely because all genotyping probes were per-
formed blindly in batches with equal number of
cases and controls. Since our diseased cohort geno-
type distribution deviated from Hardy—Weinberg
equilibrium, the mode of inheritance seems to be
additive.14 Furthermore, this situation might be
supporting evidence for the correlation between
genotype and disease since unreported or weak
associations can be detected by calculating the
HWE, even when statistically significant differences
between genotype distributions is not present.15
Allelic variants of GABABR 1 gene are plausible
risk factors for MTLE-HS development. Studies per-
formed in animal models and humans have revealed
different roles for GABAergic neurotransmission in
temporal lobe epileptogenesis. Mice lacking the
GABABR 1 subunit, although viable, exhibit sponta-
neous seizures, hyperalgesia, hyperlocomotor activ-
ity and memory impairment.16 Moreover, these mice
570 M.A. Kauffman et al.exhibited exaggerated in vitro epileptiform activity
caused by both acute and chronic consequences of
the loss of GABAB receptor function in vivo. Speci-
fically, enhancement of N-methyl-d-aspartate
(NMDA) receptor triggered synaptic processes, aris-
ing from the loss of the GABAB receptor-mediated
inhibitory postsynaptic potential (IPSP, together
with a possible promotion of depolarizing IPSPs
due to the removal of GABAB auto receptor func-
tion) likely underlying these effects.17 Furthermore
an increased expression of GABABR 1 and GABABR 2
receptors was found in the hippocampus of patients
suffering from MTLE-HS.2,18 These findings could be
indicating compensatory mechanisms for an
enhanced neuronal hyperexcitability, present in
these patients, by the inhibition of presynaptic
glutamatergic neurotransmission. Moreover, since
a subtle malformation of cortical development
could be implicated in the pathogenesis of MTLE-
HS,19 it is worthy to note the recognized role of
GABA B neurotransmission in the maturation and
organization of cortex and synaptic transmis-
sion.20,21
Nevertheless, GABA B neurotransmission was
implicated in the pathogenesis of other epileptic
syndromes, as well. For example, the injection of a
GABA B receptor agonist into the ventrobasal tha-
lamus or reticular nucleus of a rat model with
spontaneous absence seizures exacerbates the sei-
zures. By contrast, injection of a GABA B receptor
antagonist into the same regions suppresses the
spike and wave discharges.22 However, the poly-
morphism here investigated and other allelic var-
iants in GABABR 1 have not been previously found
associated with the development of absence epi-
lepsy.23 Nevertheless, different allelic variants in
other GABA receptors genes have been recognized
as risk factor for absence epilepsy24 and other epi-
lepsy syndromes.25
In summary, our results indicate that the poly-
morphism G1465A of the GABABR1 gene could be a
genetic risk marker for the development of mesial
temporal lobe epilepsy in certain populations. Alter-
natively, we cannot exclude the fact that the asso-
ciation we found could depend on the effect of other
unknown genetic variants in the GABABR1 gene in
linkage disequilibrium with the polymorphism under
investigation in our population.References
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